Per Norlén (CEO)
Per Norlén - born 1970, CEO since 2015, Chief Medical Officer (CMO) since 2010 – is a registered medical doctor with a doctoral degree and specialist doctor in clinical pharmacology, and associate professor in experimental and clinical pharmacology at Lund University. Per Norlén has 25 years of research experience in pharmacology including 14 years of experience in clinical drug development with a focus on clinical phase I/II studies. Member of the Management Team since 2010.
Other current positions: Board member of Atlas Therapeutics AB and A Bioscience Incentive AB.
Holdings in Alligator: 100,500 shares, 200,000 warrants and 250,000 employee stock options.
Per-Olof Schrewelius (CFO)
Other current positions: None
Holdings in Alligator: 1,800 shares and 125,000 warrants.
Christina Furebring (SVP Research and Development)
Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB.
Holdings in Alligator: 100,000 shares, 120,000 warrants and 150,000 employee stock options.
Rein Piir (VP Investor Relations)
Other current positions: Chairman and CEO of Piir & Partner AB.Board member of Integrative Research Laboratories Sweden AB, L. E. Svensson Snickeri Aktiebolag and Trygga Pengar i Mobilen Sverige AB.
Holdings in Alligator: 5,000 shares.